News, Infos & good to know WKN: A14XC6 ISIN: US63016Q1022 Kürzel: 26C Forum: Aktien User: Lirumlarum1

Anscheinend arbeitet ImmunityBio gerade mit dem US Militär an einer HIV Lösung. In einem veröffentlichten Schreiben wird ImmunityBio's Anktiva n-803 im Kampf gegen HIV vom US Militär getestet. 😮 Wenn ich den Link dazu habe, liefere ich den nach.

@NantKwest 12 hours ago: Our organization cares deeply and works tirelessly to deliver on our mission of improving the lives of patients worldwide. #Immunotherapy #NaturalKillerCells

bit . ly

Today, ImmunityBio has announced the appointment of John Brennan and Wesley Clark to the company's board of directors. Learn more: https://***/UDSy1A1RRA?amp=1

https://www.busines.sinsider.co.za/a-new-covid-19-vaccine-trial-has-started-in-sa-targeting-the-501yv2-variant-2021-2

Cape Town is testing a Covid-19 vaccine designed to protect against new variants https://qz.com/africa/1975820/south-africa-is-testing-a-covid-19-variant-proof-vaccine/?utm_source=google-news

University of Cape Town (UCT) researchers are expected to start the Phase 1 clinical trial of the hAd5 T-cell COVID-19 vaccine candidate this month at the Wellcome Centre for Infectious Diseases Research in Africa’s (CIDRI-Africa) Khayelitsha clinical research site. This comes after recently receiving approval from the South African Health Products Regulatory Authority. The vaccine is being developed by ImmunityBio and manufactured by NantKwest. https://www.news.uct.ac.za/article/-2021-02-18-uct-scientists-to-start-phase-1-clinical-trial-of-covid-19-vaccine-candidate

Bisher haben Institutionelle Investoren im 1. Quartal 2021 für 67 Millionen Dollar Aktien von NantKwest gekauft und für 1,87 Millionen Dollar verkauft.

-Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate -Metastatic Pancreatic Cancer Trials overall survival and 15 out of 18 (83%) of patients enrolled with second-line or greater pancreatic cancer remain alive to date -preclinical data demonstrating that ImmunityBio’s AnktivaÔ (IL-15 superagonist also known as N-803) improves interferon-gamma (IFN-g) production and killing of tumor of cells in vitro and in vivo by CD34+ progenitor-derived natural killer (NK) cells. Anktiva is currently being evaluated in late-stage clinical trials in combination with NantKwest’s (NASDAQ: NK) NK cell therapies for multiple indications including metastatic pancreatic cancer, triple negative breast cancer (TNBC), bladder cancer and lung cancer. -Natural killer immune cells engineered to target the PD-L1 molecule can directly kill tumour cells in mice and reduce the numbers of immunosuppressive cells harbouring PD-L1 in mice and humans -National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested Studies demonstrated the ability of PD-L1 t-haNK to kill 20 out of 20 human cancer cell lines tested, including triple negative breast cancer (TNBC) and lung, urogenital, and gastric cancer cells  -Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin’s Lymphoma) when Natural Killer cells and T cells are activated simultaneously -NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein -NantKwest and ImmunityBio Present Results of Landmark Trial of First-in-Human Natural Killer Cell Combination Immunotherapy with Durable, Complete Response Data and 78% Disease Control in Refractory Triple Negative Breast Cancer at SABCS -NantKwest Announces Presentation of Positive Phase 2 Clinical Data of Natural Killer Cell Therapy in Metastatic Merkel Cell Carcinoma at SITC 2019 One of these patients achieved a radiologic complete response, and the second a durable partial response with more than 75% tumor regression and no subsequent therapy (response ongoing to date). -NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients

Und Merck ist nur ein Beispiel, andere Pharmariesen verdienen auch Milliarden mit ihren Medikamenten/Behandlungen und keiner der Konkurrenz kommt an die Ergebnisse von NantKwest/ImmunityBio auch nur annähernd heran.

Warum NantKwest immer noch stark unterbewertet ist: ImmunityBio wird mit ungefähr 4,2 Mrd. Dollar bewertet, NantKwest ist zum Kurs von 34$ 3,7Mrd. Dollar wert, das sind 7,9Mrd. Dollar, das ist ein absoluter Witz, wenn man die gigantische Pipeline, deren Fortschritt (11 Studien in Phase 2/3) und die bahnbrechenden Ergebnisse in Relation zu anderen Unternehmen stellt. Merk verdient mit seinem Krebsmedikament Pembrolizumab/Keytruda 14,4 Milliarden Dollar und die behandeln damit nur Lungenkrebs und haben mit diesem Medikament eine Complete Remission Rate von 41%. NantKwest hat mit ihren Medikamenten/Behandlungen mit N 803/ h-ank/ t-ank immer eine Complete Remission Rate von mindestens 64% oder mehr, je nach Krebsart und Zustand der Patienten. Dazu muss man noch erwähnen, dass NantKwest in den meisten Studien Patienten genommen hat, deren Krebs in fortgeschrittenen Stadien war und bei denen herkömmliche Behandlungen fehlgeschlagen sind und diese durch die Chemotherapien und andere, vorherige Behandlungen, schwer körperlich und immunsystemtechnisch angeschlagen sind. Also kann man sich ganz leicht vorstellen was für gigantische Summen da zusammenkommen, wenn man mit einem erfolgreicheren Medikament/ erfolgreicherer Behandlung, mehrere Krebsarten und somit auch Patienten behandeln kann!

ImmunityBio Announces ASCO Genitourinary Cancer symposium presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate ImmunityBio Announces ASCO Genitourinary Cancer symposium presentation of  Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate QUILT 3.032 study completes planned enrollment of BCG unresponsive non-muscle invasive bladder cancer CIS cohort with 59% probability of patients maintaining complete response for at least 12 months Over 87.5% of patients in this study have avoided a cystectomy to date FDA Breakthrough Therapy designation and Accelerated Approval for ImmunityBio’s superagonist AnktivaÔ N-803 in this indication https://ir.nantkwest.com/news-releases/news-release-details/immunitybio-announces-asco-genitourinary-cancer-symposium

Nantkwest on Twitter vor 12 Std.: NantKwest and ImmunityBio have developed and manufactured an oral vaccine candidate that could potentially solve the growing issue of new variants of COVID-19 that have begun to appear across the globe Read more: https://t.co/aZgPnoYaSg?amp=1

Kaum Wirkung bei Mutante Südafrika bittet um Impfstoff-Rücknahme Vergangene Woche erhält Südafrika eine Million Dosen des Impfstoffes von Astrazeneca. Der schützt aber kaum gegen die im Land vorherrschende Corona-Variante. Die Regierung bittet den Hersteller aus Indien deshalb, das Mittel zurückzunehmen. https://www.n-tv.de/22364310